Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Unicycive TherapeuticsUNCY +3.30%35 Cash Ratio is 3.28 as of Jun. 2026, which is 100% above its 10-year median of 1.64. GuruFocus rates UNCY with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 1,355 Biotechnology companies, Unicycive Therapeutics ranks better than 52.62% on this metric.
Unicycive Therapeutics has a Cash Ratio of 3.28. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Unicycive Therapeutics's Cash Ratio or its related term are showing as below:
UNCY'
s Cash Ratio Range Over the Past 10 Years
Min: 0.02 Med: 1.64 Max: 22.94
Current: 3.28
During the past 7 years, Unicycive Therapeutics's highest Cash Ratio was 22.94. The lowest was 0.02. And the median was 1.64.
UNCY's Cash Ratio is ranked better than 52.62% of 1355
companies
in the Biotechnology industry
Industry Median: 2.96
vs UNCY: 3.28
Unicycive Therapeutics (NAS:UNCY) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Unicycive Therapeutics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Unicycive Therapeutics Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Unicycive Therapeutics's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Unicycive Therapeutics's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Unicycive Therapeutics (UNCY) has a Cash Ratio of 3.28 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Unicycive Therapeutics and its competitors. This is 100% above median its historical median of 1.64. Over the past decade, Unicycive Therapeutics' Cash Ratio has ranged from 0.02 to 22.94. According to the industry distribution chart, Unicycive Therapeutics ranks #642 out of 1355 companies in the Biotechnology industry, placing it in the top 47.4%.
Is Unicycive Therapeutics' Cash Ratio too high?
Unicycive Therapeutics' current Cash Ratio of 3.28 is 100% above median its 10-year median of 1.64. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 22.94. The Biotechnology industry median Cash Ratio is 2.96. Unicycive Therapeutics' value of 3.28 is 10.8% above this industry median. Based on the distribution chart, Unicycive Therapeutics ranks #642 out of 1355 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Unicycive Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Unicycive Therapeutics' Cash Ratio compare to CNTN and MIST?
According to the Biotechnology industry distribution chart, Unicycive Therapeutics ranks #642 out of 1355 companies for Cash Ratio. This puts Unicycive Therapeutics in the upper half of its industry. The industry median Cash Ratio is 2.96. Unicycive Therapeutics' value of 3.28 is 10.8% above this benchmark. Historically, Unicycive Therapeutics' own Cash Ratio has ranged from 0.02 to 22.94 over the past decade. While the company's 10-year median is 1.64 vs. the industry median of 2.96, Unicycive Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.96, based on 1,355 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Unicycive Therapeutics's current Cash Ratio of 3.28 is 10.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Unicycive Therapeutics and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Unicycive Therapeutics's current Cash Ratio is 3.28, which is 100% above median its own 10-year median of 1.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Unicycive Therapeutics stock overvalued right now?
Unicycive Therapeutics (UNCY) has a current Cash Ratio of 3.28. The current Cash Ratio is 3.28, which is 100% above median its 10-year median of 1.64 and 10.8% above the Biotechnology industry median of 2.96. Unicycive Therapeutics' overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Unicycive Therapeutics (UNCY), the current Cash Ratio is 3.28 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
35GF Score
Get the complete analysis for UNCY
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
UNCY has been successfully added to your 
